Ipca Laboratories Latest Updates

Stock Hits 52-Week HighIpca Labs' stock reached a new 52-week high of ₹1,624 on March 17, 2026. This rally was supported by high trading volumes and follows a period of consistent financial performance, with the stock gaining approximately 18% over the past year. As of today, the stock is trading around ₹1,562, maintaining its position above major moving averages (50-day and 200-day SMAs). Manufacturing and Regulatory Updates The company recently achieved a major operational milestone with the commencement of commercial production at its new manufacturing unit in Village Hingani, Wardha district, on February 9, 2026. On the regulatory front, the USFDA completed an inspection of the Tarapur API facility in December 2025, issuing a Form 483 with three observations. The company has stated it is working closely with the regulator to resolve these issues, which is critical for its plans to ramp up its U.S. generics business. Strategic Therapy Expansion Ipca is actively restructuring its domestic portfolio to move beyond its traditional strength in pain management (the Zerodol franchise). The company is now focusing on high-growth segments such as cardiology, central nervous system (CNS), and high-end cosmo-dermatology. In Q3, while the anti-malarial segment faced a drag (down 21%), these newer therapy areas saw robust growth, with the dermatology and CNS segments growing by 22% and 19% respectively. Unichem Integration and U.S. OutlookThe integration of Unichem Laboratories is progressing, with a focus on utilizing Unichem's underused manufacturing capacity to improve overall export margins. Ipca currently has roughly 35 U.S. registrations and plans to commercialize an additional 5–7 molecules over the next 12–15 months. Management expects the U.S. business to see a more meaningful revival starting in FY27 as more products are relaunched following recent regulatory clearances.